Arqule Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Arqule Inc (ARQL) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Arqule Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 5M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-82.6% annualized vs trailing 12 months).
- Peer revenue share: Arqule Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ARQL Sales vs. its Competitors, Q3 2019
Arqule Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
API endpoints for this dataset
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs -95.8% for Arqule Inc. Arqule Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Arqule Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Arqule Inc | - | - | - | Yes |
| High-Confidence Competitors (131) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ARQL Stock Performance relative to its Competitors
ARQL Stock Performance relative to High-Confidence Competitors
Arqule Inc's Competitors Named by the Company
Competitive relationships identified from Arqule Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Novartis International AG | Company report | 85% |
| AstraZeneca plc | Company report | 85% |
| Keros Therapeutics Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Pfizer Inc. | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Bayer AG | Company report | 85% |
| Marker Therapeutics inc | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Propanc Biopharma Inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Petvivo Holdings Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Abivax Sa | Company report | 85% |
| Agomab Therapeutics Nv | Company report | 85% |
| Palatin Technologies Inc | Company report | 85% |
| Elanco Animal Health Incorporated | Company report | 85% |
| Allarity Therapeutics Inc | Company report | 85% |
| Sunshine Biopharma Inc | Company report | 85% |
| Oragenics Inc | Company report | 85% |
| Terns Pharmaceuticals Inc | Company report | 85% |
| Absci Corp | Company report | 85% |
| Vaxcyte Inc | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Qnity Electronics Inc | Company report | 85% |
| Mangoceuticals Inc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Bnb Plus Corp | Company report | 85% |
| Northwest Biotherapeutics Inc | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Tempest Therapeutics Inc | Company report | 85% |
| Puretech Health Plc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Mosaic Immunoengineering Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Arqule Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Arqule Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.